Transforming the prevention of pregnancy complications

Pregnancy complications affect approximately 25% of pregnancies, with preeclampsia being one of the main causes of maternal and neonatal morbidity.

Despite its clinical impact, current screening strategies present significant limitations:

Non-standardised protocols

Subjective, operator-dependent assessment

Limited capacity to allow effective preventive intervention

There is a significant unmet clinical need in obstetrics.

The clinical challenge: detecting before the disease appears

Preeclampsia is a multisystem disorder characterised by new-onset hypertension and organ dysfunction..

The main challenge is not its treatment, but detection in preclinical stages, when intervention can modify the course of the disease.

imagen de una mujer sosteniendo a su bebé en el pecho

The biological origin of preeclampsia

Nuestra investigación identifica la resistencia a la decidualización endometrial como un mecanismo implicado en el desarrollo de la preeclampsia.
Esta alteración se asocia con:

  • Preparación endometrial deficiente.
  • Alteración de la comunicación materno-fetal.
  • Placentación y remodelado vascular anómalos.

Estas alteraciones preceden a las manifestaciones clínicas de la preeclampsia y se asocian con señales moleculares tempranas detectables en sangre materna mediante ARNlc.

Our solution: MaiRa

First-trimester preeclampsia risk assessment based on:

Maternal blood sample

Taken between weeks 9 and 14

Molecular analysis

Extraction of circulating cell-free RNA from plasma and analysis with massive sequencing (NGS)

Interpretation of results

Predicción individual de riesgo con modelo predictivo basado en IA

Report

Results to support medical decisions

This approach makes it possible to move from the observation of symptoms to prediction based on molecular biology.

Clinical advantages

MaiRa allows an early risk assessment:

Sample collection: weeks 9–14

Up to 18 weeks ahead of the appearance of symptoms

Assessment based on molecular biology (not on clinical manifestations)

Simple clinical workflow (no need for complex additional tests)

Compatible with NIPT (same blood sample)

Clinical value

Early identification of risk makes it possible to:

Risk stratification

Preventive intervention

Personalised monitoring

Expected clinical impact

Impact on clinical practice

For the patient

For the specialist

For the healthcare system

Scientific evidence

MaiRa is born from a scientific approach designed to transform prenatal diagnosis, shifting the detection of complications from the appearance of symptoms towards the early identification of biological signals.
Through the PREMOM, hemos identificado una señal molecular temprana basada en ARNlc habiendo desarrollado y validado un modelo predictivo capaz de anticipar el riesgo de preeclampsia antes de su manifestación clínica. Este trabajo ha sentado las bases de una nueva aproximación en la medicina materno-fetal, respaldada por publicaciones científicas de alto impacto.

Beyond preeclampsia: a technological platform

The combination of:

Makes it possible to expand the model towards:

iPremom is evolving towards a global platform for predictive prenatal diagnosis

Test documentation

Download here all the documentation needed to carry out the test: instructions, request form, and information sheet and informed consent.

Instructions for clinics and sample collection centres

Test request form (TRF)

Information sheet and consent (IC)

A new paradigm in obstetrics

The current model is reactive.
MaiRa introduces an approach based on:
Early detection → Preventive intervention → Pregnancy without preeclampsia